Deal With Cancer
News

IL-17 promotes mammary tumor progression by changing the behavior of tumor cells and eliciting tumorigenic neutrophils recruitment

Deal With Cancer Team · 20 Nov 2026

The aggressiveness of invasive ductal carcinoma (IDC) of the breast is associated with increased IL-17 levels. Studying the role of IL-17 in invasive breast tumor pathogenesis, we found that metastatic primary tumor-infiltrating T lymphocytes produced elevated levels of IL-17, whereas IL-17 neutralization inhibited tumor growth and prevented the migration of neutrophils and tumor cells to secondary disease sites. Tumorigenic neutrophils promote disease progression, producing CXCL1, MMP9, VEGF and TNF
, and their depletion suppressed tumor growth. IL-17A also induced IL-6 and CCL20 production in metastatic tumor cells, favoring the recruitment and differentiation of Th17. In addition, IL-17A changed the gene expression profile and the behavior of non-metastatic tumor cells, causing tumor growth in vivo, confirming the pro-tumor role of IL-17. Furthermore, high IL-17 expression was associated with lower disease-free survival (DFS) and worse prognosis in IDC patients. Thus, IL-17 blockade represents an attractive approach for the control of invasive breast tumors.